Stock Markets February 9, 2026

Moody's Keeps Fortrea at B3, Moves Outlook to Stable as Leverage Is Expected to Ease

Rating agency affirms B3 family rating and related debt scores, cites high leverage but anticipates operating improvements and adequate liquidity

By Caleb Monroe
Moody's Keeps Fortrea at B3, Moves Outlook to Stable as Leverage Is Expected to Ease

Moody's Ratings has affirmed Fortrea Holdings Inc.'s B3 Corporate Family Rating and associated debt ratings, while revising the outlook from negative to stable. The agency expects adjusted debt-to-EBITDA to fall below 10x within 12 to 18 months, though leverage remains very high and governance risks are material to the rating.

Key Points

  • Moody's affirmed Fortrea's B3 Corporate Family Rating and related B3 ratings on senior secured debt, keeping the SGL-3 liquidity score.
  • The agency expects adjusted debt-to-EBITDA to fall below 10x within 12 to 18 months, with current adjusted leverage at 12.3x (15.6x including the $300 million securitization) for the year ended September 30, 2025.
  • Liquidity is supported by roughly $131 million in cash and a $450 million revolving credit facility expiring in June 2028, which had no borrowings as of September 30, 2025.

Moody's Ratings has affirmed Fortrea Holdings Inc.'s B3 Corporate Family Rating and simultaneously updated the company's outlook from negative to stable.

The rating firm also maintained a B3-PD Probability of Default Rating, B3 ratings on the company's senior secured bank credit facilities and senior secured notes, and kept the Speculative Grade Liquidity rating at SGL-3.

Moody's assessment projects that Fortrea's operating performance will improve over the coming 12 to 18 months, leading to a reduction in financial leverage. The agency expects adjusted debt-to-EBITDA to decline to below 10.0 times within that timeframe. In its calculations, Moody's does not add back stock compensation expense to EBITDA and treats the company's $300 million accounts receivable securitization facility as a debt-like obligation.

The stable outlook reflects Moody's view that credit metrics will strengthen modestly over the next 12 to 18 months and that liquidity will remain adequate. The agency cited modestly positive free cash flow and full access to the company's revolving credit facility as supporting factors for liquidity.

For the twelve-month period ended September 30, 2025, Fortrea's adjusted debt/EBITDA stood at 12.3x, and 15.6x when the accounts receivable securitization facility is included. Moody's noted that part of the expected improvement in leverage stems from an anticipated reduction in stock compensation expense.

As of September 30, 2025, Fortrea reported approximately $131 million in cash and cash equivalents. The company has a $450 million revolving credit facility that expires in June 2028; Moody's reports there were no borrowings under that facility as of September 30, 2025.

Despite the revised outlook, Moody's emphasized that governance risk factors materially informed the rating action. The agency pointed to execution risk and management's track record as important considerations and stated that Fortrea's financial leverage remains significantly higher than initially anticipated.

Moody's set clear benchmarks for upgrading the rating: Fortrea would need to demonstrate sustained profitable growth, improved liquidity, and strong free cash flow, while keeping adjusted debt/EBITDA below 5.0 times. Conversely, the agency warned that a failure to improve operating performance or any weakening of liquidity could prompt a downgrade.


Key financial metrics cited by Moody's remain focused on leverage, cash position, and access to credit. The agency's treatment of certain items - specifically excluding stock compensation add-backs from EBITDA and treating the $300 million securitization as debt-like - affects the reported leverage ratios and frames the pathway to potential rating improvement.

Risks

  • Persistent high leverage - Fortrea's adjusted debt/EBITDA remains materially elevated and could impede rating improvement; this affects credit markets and the broader pharmaceutical services sector.
  • Governance and execution risk - Moody's flagged management track record and execution risk as material factors that could constrain the rating or lead to negative rating actions.
  • Liquidity deterioration or weaker operating performance - Failure to generate the modestly positive free cash flow Moody's expects, or restricted access to the revolving facility, could prompt a downgrade and affect financing conditions for the company.

More from Stock Markets

Moscow Stocks Finish Mixed as MOEX Index Holds Steady Feb 22, 2026 Rolls-Royce Poised to Announce Up to £1.5 Billion Share Buyback Alongside Annual Results Feb 22, 2026 DAE Capital Nears Purchase of Macquarie AirFinance, Sources Say Feb 22, 2026 S&P 500 Shows Signs of Tightening Range; Strategist Sees Potential for a Big Move Feb 22, 2026 Supreme Court to Clarify Reach of Helms-Burton Act in Multi-Billion Dollar Cuba Claims Feb 22, 2026